Isotretinoin revisited.
Isotretinoin (13-cis-retinoic acid) remains the drug of choice for treatment of severe, recalcitrant nodulocystic acne that is unresponsive to conventional therapy, including oral antibiotics. The drug has been shown to produce dramatic clearing of lesions and prolonged remissions. The length of remission may be dependent on both the dosage used and the duration of therapy. Since fetal malformations have been observed in infants born of mothers taking isotretinoin during pregnancy, it is mandatory to prevent women who are pregnant or may become pregnant during treatment from taking isotretinoin. Because the half-life of isotretinoin is ten to twenty hours, and because it is eliminated from the body rapidly enough, women may become pregnant one month after discontinuation of therapy without an increased risk of birth defects. Common side effects of the drug include mucocutaneous reactions, serum lipid alterations, eye irritation, and myalgias. Less commonly observed are hyperostoses and exuberant granulation tissue, and rarely, pseudotumor cerebri. Recommendations for substantially reducing or eliminating these effects are made.
Shalita
A R
AR
Department of Dermatology, State University of New York Health Science Center, Brooklyn.
Armstrong
R B
RB
Leyden
J J
JJ
Pochi
P E
PE
Strauss
J S
JS
D000014:Abnormalities, Drug-Induced; D000152:Acne Vulgaris / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D011247:Pregnancy; D012627:Sebaceous Glands / Q000187:drug effects; D012629:Sebum / Q000187:drug effects; D014280:Triglycerides / Q000097:blood
D014280:Triglycerides; D015474:Isotretinoin